Autopsy report · NCT05011058
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
Cause of deathFunding or business
“Sponsor Decision”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 3 years 8 months before it stopped.
- 102 participants enrolled.
- Results were posted on the registry 6 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Viracta Therapeutics, Inc.
- Sponsor type
- Industry
- Conditions
- Epstein-Barr Virus Associated Lymphoma; EBV-Positive DLBCL, NOS; EBV-Related Non-Hodgkin Lymphoma; EBV Related PTCL, NOS; EBV-Related Hodgkin Lymphoma; EBV-Related PTLD
- Interventions
- Nanatinostat in combination with valganciclovir
- Participants
- 102
- Sites
- 62
- Countries
- Australia, Brazil, Canada, France, Germany, Israel, Italy, Malaysia, Singapore, South Korea, Spain, Taiwan and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.